Status: Recruiting
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
The purpose of this Phase 1, first in human open-label study is to assess the safety and tolerability of TRX-103 in patients with hematological malignancies undergoing HLA-mismatched related or unrelated hematopoietic stem cell transplantation (HSCT). It is anticipated that up to 36 Subjects will be enrolled during a 18-24 month enrollment period. TRX-103 will be infused one time post HSCT.
Participants needed: 36
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Tr1X, Inc.Updated: Apr 15, 2025Locations: 5
Eligibility criteria
Subjects with one of the following hematologic malignancies: Acute Lymphoblastic... [+9]
Prior allogeneic bone marrow, peripheral blood, or cord blood HSCT. [+8]